As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Teva has priced the generic at $1,165 per month, slightly below the $1,350 cost of Saxenda
O perfil de efeitos colaterais da Retatrutida semelhante aos anlogos do receptor de GLP-1 isolado j so usadas para o tratamento da obesidade e/ou diabetes, como a semaglutida (Princpio ativo do Wegovy, Ozempic, Rybelsus), liraglutida (Princpio ativo do Victoza e Saxenda), dulaglutida (Princpio ativo presente Trulicity) ou do anlago do receptor de GLP-1 e GIP : Tirzepatida (Princpio ativo do Mounjaro)
For comprehensive long-term safety data, see our long-term safety analysis and dysesthesia guide
If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUVIA